Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.blissgvs.com | |
Market Cap | 742.09 Cr. | |
Enterprise Value(EV) | 695.65 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 8.37 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 8.51 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 32.41 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 84.82 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 0.84 | Calculated using Price: 71.20 |
Dividend Yield | 0.70 | Period Ending 2022-03 |
No. of Shares Subscribed | 10.42 Cr. | 104,152,672 Shares |
FaceValue | 1 | |
Company Profile | ||
It is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market. The company's most unique product is ‘Today Vaginal Contraceptive', a safe female contraceptive aimed at furthering Planned Parenthood and is also an established method for preventing conception. Bliss also manufactures to US specification vaginal pessaries of Clotrimazole & Povidone Iodine in addition to Anal Suppositories for treatment of piles. The company also manufacture wide range of Pessary Formulations, Suppository Formulations, Calcium Preparation, Protein Powders, Iron Preparation, Antibiotics, Analgesic & Antipyretics, Respiratory, Anti-inflammatory, Dermatological Preparations, Anti-Diarrhoeal products. |
1 Day |
|
+0.95% |
1 Week |
|
-0.48% |
1 Month |
|
-10.50% |
3 Month |
|
-1.86% |
6 Month |
|
-6.75% |
1 Year |
|
-7.47% |
2 Year |
|
-27.86% |
5 Year |
|
-63.55% |
10 Year |
|
+166.67% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 15.17 | 19.74 | 26.73 | 25.06 | 17.34 | 21.43 | 13.79 | 9.64 | 2.88 | |
Return on Capital Employed (%) | 20.56 | 23.57 | 32.07 | 31.06 | 24.61 | 26.58 | 17.02 | 12.49 | 6.37 | |
Return on Assets (%) | 6.46 | 9.01 | 13.04 | 11.88 | 9.42 | 14.35 | 9.86 | 7.03 | 2.12 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 287 | 337 | 413 | 487 | 536 | 646 | 736 | 808 | 819 | 854 | |
Non Curr. Liab. | 96 | 68 | 50 | 33 | 13 | 38 | 46 | 45 | 29 | 43 | |
Curr. Liab. | 308 | 243 | 379 | 437 | 299 | 207 | 231 | 204 | 233 | 172 | |
Minority Int. | 10 | 15 | 33 | 66 | 11 | 14 | 15 | 20 | 28 | 32 | |
Equity & Liab. | 700 | 662 | 874 | 1,023 | 860 | 905 | 1,027 | 1,077 | 1,109 | 1,101 | |
Non Curr. Assets | 230 | 245 | 291 | 457 | 170 | 211 | 257 | 312 | 333 | 383 | |
Curr. Assets | 469 | 417 | 583 | 566 | 690 | 693 | 770 | 765 | 776 | 718 | |
Misc. Exp. not W/O | 1 | 0 | |||||||||
Total Assets | 700 | 662 | 874 | 1,023 | 860 | 905 | 1,027 | 1,077 | 1,109 | 1,101 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 345 | 407 | 547 | 798 | 815 | 899 | 689 | 577 | 747 | 734 | |
Other Income | 28 | 20 | 24 | 13 | 27 | 38 | 39 | 22 | 31 | 27 | |
Total Income | 373 | 427 | 571 | 811 | 841 | 936 | 728 | 599 | 779 | 761 | |
Total Expenditure | -273 | -304 | -391 | -596 | -618 | -741 | -566 | -471 | -629 | -603 | |
PBIDT | 99 | 124 | 180 | 215 | 224 | 195 | 163 | 129 | 150 | 158 | |
Interest | -18 | -16 | -19 | -20 | -23 | -4 | -8 | -7 | -5 | -7 | |
Depreciation | -11 | -11 | -13 | -20 | -21 | -9 | -13 | -17 | -17 | -18 | |
Taxation | -30 | -35 | -48 | -63 | -57 | -55 | -34 | -30 | -31 | -37 | |
Exceptional Items | -34 | -13 | -74 | ||||||||
PAT | 41 | 61 | 100 | 113 | 89 | 127 | 95 | 74 | 23 | 97 | |
Minority Interest | 0 | -1 | -18 | -31 | -30 | -3 | 2 | -5 | -8 | -10 | |
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 41 | 60 | 82 | 82 | 59 | 124 | 97 | 68 | 15 | 87 | |
Adjusted EPS | 4 | 6 | 8 | 8 | 6 | 12 | 9 | 7 | 1 | 8 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 7 | 41 | 38 | 113 | 289 | 18 | 40 | 47 | 64 | 135 | |
Cash Fr. Inv. | -124 | -11 | -29 | -50 | -231 | 50 | -74 | -48 | -47 | -93 | |
Cash Fr. Finan. | 110 | -8 | -42 | -40 | -10 | -76 | 17 | -6 | -21 | -24 | |
Net Change | -8 | 22 | -33 | 23 | 48 | -8 | -17 | -8 | -4 | 19 | |
Cash & Cash Eqvt | 50 | 50 | 5 | 28 | 47 | 37 | 15 | 15 | 13 | 22 |
Fri, 31 Mar 2023
Closure of Trading Window Pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 and in accordance with the Code of Internal Procedures and Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons the Trading window for dealing in securities/shares of Bliss GVS Pharma Limited will remain closed for Insiders Designated Persons and their immediate relatives of the Company with effect from Saturday April 01 2023 until 48 hours after the announcement of the Audited Financial results of the Company for the quarter and year ended March 31 2023. The Board meeting for the declaration of Audited Financial Results for the quarter and year ended March 31 2023 shall be intimated later.Accordingly Insiders Designated Persons and their immediate relatives are advised not to trade (buy or sell or pledge etc.) in the securities/shares of the Company during the aforesaid period of closure of the Trading Window. |
Thu, 23 Mar 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the Registrar and Share Transfer Agent of Company M/s. Universal Capital Securities Private Limited have received a request to issue of duplicate share certificate consequent to loss of share certificate from the shareholder. |
Sat, 18 Mar 2023
Intimation About Completion Of US FDA Inspection At Plot 11 Of The Company This is to inform you that the United States Food and Drug Administration (US FDA) conducted a Pre-Approval Inspection (PAI) and Good Manufacturing Practice (GMP) inspection at the Companys manufacturing unit at Plot No. 11 Survey No. 38/1 Dewan Udyog Nagar Aliyali Village Palghar 401404 Maharashtra from Monday March 13 2023 to Friday March 17 2023. After the inspection the US FDA issued a Form 483 with 3 minor observations. The observations are procedural in nature. None of the observations relate to data integrity. The Company shall prepare detailed response to the observations which will be submitted to the US FDA within the stipulated timelines. The Company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations. |
Fri, 31 Mar 2023 |
|
|
|
|
|